Interview with Robert Dahan, President, AstraZeneca France
You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a…
Address: 1 Place Louis Renault, Rueil-Malmaison cedex 92844,France
Tel: 33 (0)1 41 29 40 00
Web: http://www.astrazeneca.fr/accueil/
AstraZeneca provides medical professionals and patients know how and drugs already widely recognized. The French subsidiary of AstraZeneca was the first European subsidiary of the group and the third in the world after the United States and Japan.
With a turnover of 1.23 billion euros in 2008, AstraZeneca is the 6th largest pharmaceutical company in France while employing 1,900 people.
In France, AstraZeneca is involved in all stages of the life of the drug research, development, production, marketing. Besides the headquarters in Rueil-Malmaison and medical networks present throughout the territory, the company has a center of Cancer Research in Reims and two industrial sites in Dunkirk and Reims.
AstraZeneca has a broad range of effective drugs and innovative, designed to combat disease in areas where medical needs are greatest.
ANESTHESIA
HEART
GASTROINTESTINAL ENTEROLOGY
INFECTIOLOGY
ONCOLOGY
RESPIRATORY
CENTRAL NERVOUS SYSTEM
You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a…
Bernard Vanhove, CEO and Maryvonne Hiance, Chairman of Effimune, an immune regulation biotech, discuss their novel approach to developing immunotherapies, their partnership and commercialization strategies, their perspective on the landscape…
Dominique Costantini, the CEO of OSE Pharma, a French biotech company developing immunotherapy products against late-stage (invasive and metastatic) cancer discusses the company’s unique targeted approach based on a patented…
The President of Pfizer France reveals how the biggest challenge the French pharma industry faces is to gain credit for its contribution to improve people´s quality of life; why France…
The president of the Institut Pasteur talks about how they must build on their differentiating factors, with a focus on interdisciplinary research, why they are not a French institute with…
Mr Martinez, President of Santen France, reveals how Santen’s decision to acquire the French pharmaceutical company Novagali in 2011, was based on its desire to project itself as an innovative ophthalmic…
The president of HAS sheds light on the seemingly complex French healthcare system, explains HAS’ role within that context and provides an honest assessment of the system’s advantages and flaws.…
Mr. Finn Søndergaard, CEO of Intsel Chimos, an independent French laboratory with a long history of expertise in the import of medicines for patients in a therapeutic impasse, highlights Intsel…
Mr. Michel Finance, CEO of Theradiag, a leading French player in in vitro diagnostics and the novel field of theranostics (a combination of treatment and diagnosis), discusses the major restructuring…
The president and founder of FSNB Health & Care, a healthcare consultancy, discusses his motivations behind the creation of his company, as well as the challenges and opportunities the pharmaceutical…
ALK’s Denis Delval reveals how France is number one in terms of volumes for the group and number two in terms of revenues, just behind Germany; how the four Danes…
The president and CEO of AREVA Med, the medical subsidiary of AREVA Group, the biggest nuclear company in the world, discusses the circumstances that inspired AREVA’s foray into nuclear medicine,…
The President of CEPS, the French pricing agency, reveals the issues around the launch of the hepatitis C drug Sovaldi in 2014 and of CEPS´ role to ensure that innovative products are available to all…
See our Cookie Privacy Policy Here
